Benign Prostatic Hyperplasia
Conditions
Brief summary
This study will evaluate the safety and effectiveness of different doses of OPK-88004 compared to placebo on serum PSA compared to placebo in men with benign prostatic hyperplasia (BPH).
Detailed description
Study SAR-202 is a phase 2 multicenter, placebo-controlled, double-blind trial to evaluate the effect of OPK-88004 doses (OPK-88004 15 mg, or OPK-88004 25 mg) on serum PSA compared to placebo in men with BPH. Approximately 115 men with BPH will be enrolled in the study, randomized 1:1:1 across three arms (placebo, OPK-88004 15 mg, or OPK-88004 25 mg). The trial will be conducted at approximately up to 35 sites within the US. The study duration for individual subjects will be up to 24 weeks and will include three phases: * a screening period (up to 4 weeks, including 1-week washout if required), * a treatment period (16 weeks), and * a follow-up period (4 weeks) Subjects will be randomized and receive their first dose of study drug at visit 2. They will begin the once daily oral dosing regimen and return every 4 weeks to the study site during the 16-week treatment period. Assessments during the study period will include vital signs, laboratory testing, weight, adverse events (AEs), concomitant drugs, and study drug compliance. Efficacy assessments will include serum PSA, LBM and fat mass by DXA scans, uroflowmetry parameters, PVR (by ultrasound), and assessment of symptoms by IPSS.
Interventions
DRUGGroup-1 (15mg, OPK-88004)
15mg, OPK-88004
DRUGGroup-2 (25 mg,OPK-88004)
25 mg,OPK-88004
OTHERPlacebo
Placebo
Sponsors
OPKO Health, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
45 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Subjects are eligible if they meet the following criteria: 1. Present with BPH-LUTS based on disease diagnostic criteria at visit 1 2. Are men aged 45 years or older at visit 1 3. Have prostate volume \>40 cm3 and \<80 cm3 assessed by TRUS at visit 1 4. Have a PSA \>1.5 and \<10.0 ng/mL at visit 1. This PSA blood draw must be performed at least 1 week after any digital rectal exam (DRE) and/or transrectal ultrasound (TRUS) procedures 5. Subjects with a PSA ≥4.0 and \<10.0 ng/mL must have documentation of a negative histologic biopsy of carcinoma of the prostate within 12 months of screening (visit 1). For subjects aged ≤80 years and who have not undergone any invasive urological procedure within 6 months, if biopsy has not been performed, then 4Kscore Test value must be \<7.5% at visit 1 6. Have laboratory tests within normal limits (with the exception of total serum or free testosterone). If laboratory test results are outside normal limits they are determined to be not clinically significant at visit 1 7. Have not received prior treatment with 5-ARIs (finasteride, dutasteride) within the past one year for any indication 8. Have not received herbal BPH preparations within 1 week of visit 1. If the subject is currently on such treatment, a 1-week washout period will be required 9. Agree not to use 5-ARIs, herbal or experimental treatments for BPH, at any time during the study. Subjects on daily PDE5i's, alpha-blockers or anticholinergic medications for BPH should remain on a stable dose during the study, unless a change in dose is medically warranted. Occasional-use PDE5i's for ED are permitted at a stable dose and frequency, however should not be taken within 72 hours prior to a study visit 10. Agree to use an acceptable method of birth control during the study and for 60 days after the last dose of IP, unless the female partner is postmenopausal. Postmenopausal is defined as a female \>50 years of age and 12 months of amenorrhea, or surgically postmenopausal 11. Are reliable and willing to make themselves available for the duration of the study, and who will comply with the required study and dosing visits and abide by the Clinical Research Site policy and procedure and study restrictions 12. Have given written informed consent
Exclusion criteria
Patients will be excluded from study enrollment if they meet any of the following criteria at visit 1: 1. History of any of the following pelvic conditions: * radical prostatectomy, pelvic surgery for removal of malignancy, or bowel resection * pelvic radiotherapy * any pelvic surgical procedure on the urinary tract, including transurethral resection of the prostate (TURP), penile implant surgery * lower urinary tract malignancy or trauma * pelvic surgery or any other pelvic procedure less than 6 months prior to visit 1 2. Lower urinary tract instrumentation (including prostate biopsy) within 6 weeks prior to screening PSA blood draw 3. History of urinary retention or lower urinary tract (bladder) stones within 1 month of visit 1 4. Minimally invasive procedures for BPH, such as prostatic stent, high intensity focused ultrasound (HIFU), holmium laser enucleation of prostate (HoLEP), interstitial laser coagulation (ILC), transurethral electroevaporation of the prostate (TUVP), transurethral microwave thermotherapy (TUMT), transurethral needle ablation (TUNA), photoselective vaporization (PVP), UroLift, within 6 weeks 5. Clinical evidence of urinary tract infection or urinary tract inflammation (including prostatitis) 6. Intravesical obstruction (eg, intravesical median lobe of the prostate) 7. Current neurologic disease or condition associated with neurogenic bladder (eg, Parkinson's disease, multiple sclerosis) 8. History of significant renal insufficiency, defined as receiving renal dialysis or having an estimated creatinine clearance \<45 mL/min 9. Active hepatobiliary disease or serologic evidence of active hepatitis A, B, C, hepatitis E or HIV 10. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 2X the upper limit of normal (ULN) 11. Glycosylated hemoglobin (HbA1c) \>9% 12. Hematocrit ≥50% 13. HDL-C \<35 mg/dL and LDL-C \>130 mg/dL 14. QTcB interval \>450 msec. For heart rates over 75, the ECG may be repeated after 5 minutes of resting quietly 15. Abnormality in ECG (eg, left bundle branch block, complete right bundle branch block, or delayed intraventricular conduction with a QRS interval \>120 msec) that in the opinion of the investigator places the subject at an unacceptable risk for study participation, or subject has implanted pacemaker 16. History of any of the following cardiac/coronary conditions within 90 days: * history of myocardial infarction or coronary artery bypass graft * percutaneous coronary intervention * stroke 17. Any evidence of heart disease (NYHA ≥Class II, Appendix 4) within 6 months, or are receiving treatment for congestive heart failure (CHF) 18. Any supraventricular or ventricular arrhythmia with uncontrolled ventricular response (mean heart rate \>100 bpm) at rest despite medical therapy 19. Systolic blood pressure \>160 or \<90 mm Hg or diastolic blood pressure \>100 or \<50 mm Hg as determined by a sitting measurement (if stress is suspected, retest up to two times under basal conditions), or malignant hypertension 20. Have a history or presence of prostatic carcinoma, as well as any conditions that may be exacerbated by androgenic medications such as (but not limited to) epilepsy, seizures, convulsions, migraine or polycythemia 21. History of cancer within the previous 5 years, except for excised superficial lesions (such as basal cell carcinoma and squamous cell carcinoma of the skin) 22. History of drug, alcohol, or substance abuse within 6 months 23. Have an alcohol intake of ≥3 units/day or ≥14 units/week during the study (1 unit = 12 ounces of beer, 5 ounces of wine, 1.5 ounces of distilled spirits) 24. Any condition that would interfere with subject's ability to provide informed consent or comply with study instructions, would impair ability to perform the study assessments, or would place subject at increased risk, or might confound the interpretation of the study results 25. Current treatment with androgens, antiandrogens, estrogens, or anabolic steroids within the prior 1 month. Any prior or current treatment with LHRH agonists/antagonists 26. Current treatment with potent CYP3A4 inhibitors such as itraconazole or ritonavir 27. Have taken prescription or over-the-counter medications to promote weight loss within the prior 3 months 28. Any prior use of OPK-88004 Allergic to any component of OPK-88004
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in PSA (%) to Week 16 | 16 weeks | The trial will evaluate the effect of two doses of OPK-88004 (15 mg and 25 mg) daily for 16 weeks on serum PSA compared with placebo |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Absolute Change in Lean Body Mass and Fat Mass From Baseline to 16 Weeks | 16 weeks | To assess the effect of OPK-88004 on body composition by DXA, specifically Lean Body Mass (LBM) and fat mass |
Other
| Measure | Time frame | Description |
|---|---|---|
| To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter-voided Volume (Vcomp) | 16 weeks | Analysis voided of Uroflowmetry Parameters and Postvoid Residual Volume Observed Change from Baseline to Week 16 |
| To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Peak Flow Rate (Qmax) | 16 weeks | Analysis peak flow rate of Uroflowmetry Parameters and Postvoid Residual Volume Observed Change from Baseline to Week 16 |
| International Prostate Symptom Score- IPSS | 16 weeks | To evaluate the effects of OPK-88004 on the symptoms of BPH as determined by International prostate symptom score (IPSS score), Total IPSS score as measured by the sum of questions 1 through 7, the IPSS Irritative Domain (sum of questions 2, 4 and 7), and the IPSS Obstructive Domain (sum of questions 1, 3, 5 and 6)IPSS QoL question (IPSS question 8). Mild (symptoms score less than or equal to 7), moderate (symptoms score range 8-19), severe (symptom score 20-35) |
| To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Postvoid Residual Volume (PVR) | 16 weeks | Analysis postvoid residual volume of Uroflowmetry Parameters and Postvoid Residual Volume Observed Change from Baseline to Week 16 |
| To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Mean Flow Rate (Qave) | 16 weeks | Analysis mean flow rate of Uroflowmetry Parameters and Postvoid Residual Volume Observed Change from Baseline to Week 16 |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Other Placebo Group
Placebo: Placebo | 36 |
| Drug Group 1 15mg, OPK-88004
Group-1 (15mg, OPK-88004): 15mg, OPK-88004 | 40 |
| Drug Group 2 25,mg OPK-88004
Group-2 (25 mg,OPK-88004): 25 mg,OPK-88004 | 38 |
| Total | 114 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Adverse Event | 1 | 4 | 4 |
| Overall Study | Lost to Follow-up | 0 | 0 | 1 |
| Overall Study | Physician Decision | 0 | 0 | 1 |
| Overall Study | Protocol Violation | 0 | 2 | 0 |
| Overall Study | Sponsor's decision | 6 | 9 | 7 |
| Overall Study | Withdrawal by Subject | 1 | 2 | 2 |
Baseline characteristics
| Characteristic | Drug Group 1 | Drug Group 2 | Total | Other |
|---|---|---|---|---|
| Age, Continuous | 64.5 Year STANDARD_DEVIATION 5.77 | 65.3 Year STANDARD_DEVIATION 6.01 | 64.6 Year STANDARD_DEVIATION 6.06 | 64.1 Year STANDARD_DEVIATION 6.52 |
| Body mass index (kilogram/meter^2) | 30.37 Kilogram/meter^2 STANDARD_DEVIATION 5.286 | 29.36 Kilogram/meter^2 STANDARD_DEVIATION 3.442 | 29.97 Kilogram/meter^2 STANDARD_DEVIATION 4.671 | 30.17 Kilogram/meter^2 STANDARD_DEVIATION 5.114 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 3 Participants | 5 Participants | 15 Participants | 7 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 37 Participants | 33 Participants | 99 Participants | 29 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Female | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Male | 40 Participants | 38 Participants | 114 Participants | 36 Participants |
| Weight (kilogram) | 95.31 Kilogram STANDARD_DEVIATION 19.128 | 91.35 Kilogram STANDARD_DEVIATION 13.564 | 93.88 Kilogram STANDARD_DEVIATION 16.692 | 94.97 Kilogram STANDARD_DEVIATION 16.937 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 36 | 0 / 40 | 0 / 38 |
| other Total, other adverse events | 5 / 36 | 25 / 40 | 30 / 38 |
| serious Total, serious adverse events | 0 / 36 | 0 / 40 | 2 / 38 |
Outcome results
Primary
Change From Baseline in PSA (%) to Week 16
The trial will evaluate the effect of two doses of OPK-88004 (15 mg and 25 mg) daily for 16 weeks on serum PSA compared with placebo
Time frame: 16 weeks
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Other | Change From Baseline in PSA (%) to Week 16 | -2.96 Percentage of serum PSA change | Standard Error 5.198 |
| Drug Group 1 | Change From Baseline in PSA (%) to Week 16 | -1.48 Percentage of serum PSA change | Standard Error 5.569 |
| Drug Group 2 | Change From Baseline in PSA (%) to Week 16 | -15.44 Percentage of serum PSA change | Standard Error 5.509 |
Secondary
Absolute Change in Lean Body Mass and Fat Mass From Baseline to 16 Weeks
To assess the effect of OPK-88004 on body composition by DXA, specifically Lean Body Mass (LBM) and fat mass
Time frame: 16 weeks
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Other | Absolute Change in Lean Body Mass and Fat Mass From Baseline to 16 Weeks | Change from Baseline in Lean Body Mass (g) to Week 16 | 37.8 gram | Standard Error 439.62 |
| Other | Absolute Change in Lean Body Mass and Fat Mass From Baseline to 16 Weeks | Change from Baseline in Fat Mass (g) to Week 16 | -198.2 gram | Standard Error 326.84 |
| Drug Group 1 | Absolute Change in Lean Body Mass and Fat Mass From Baseline to 16 Weeks | Change from Baseline in Fat Mass (g) to Week 16 | -1468.7 gram | Standard Error 373.06 |
| Drug Group 1 | Absolute Change in Lean Body Mass and Fat Mass From Baseline to 16 Weeks | Change from Baseline in Lean Body Mass (g) to Week 16 | 1610.3 gram | Standard Error 489.45 |
| Drug Group 2 | Absolute Change in Lean Body Mass and Fat Mass From Baseline to 16 Weeks | Change from Baseline in Lean Body Mass (g) to Week 16 | 1961.6 gram | Standard Error 522.58 |
| Drug Group 2 | Absolute Change in Lean Body Mass and Fat Mass From Baseline to 16 Weeks | Change from Baseline in Fat Mass (g) to Week 16 | -1491.3 gram | Standard Error 388.98 |
Other Pre-specified
International Prostate Symptom Score- IPSS
To evaluate the effects of OPK-88004 on the symptoms of BPH as determined by International prostate symptom score (IPSS score), Total IPSS score as measured by the sum of questions 1 through 7, the IPSS Irritative Domain (sum of questions 2, 4 and 7), and the IPSS Obstructive Domain (sum of questions 1, 3, 5 and 6)IPSS QoL question (IPSS question 8). Mild (symptoms score less than or equal to 7), moderate (symptoms score range 8-19), severe (symptom score 20-35)
Time frame: 16 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Other | International Prostate Symptom Score- IPSS | 14.0 Total IPSS score | Standard Deviation 7.7 |
| Drug Group 1 | International Prostate Symptom Score- IPSS | 12.8 Total IPSS score | Standard Deviation 6.21 |
| Drug Group 2 | International Prostate Symptom Score- IPSS | 14.2 Total IPSS score | Standard Deviation 7.28 |
Other Pre-specified
To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Mean Flow Rate (Qave)
Analysis mean flow rate of Uroflowmetry Parameters and Postvoid Residual Volume Observed Change from Baseline to Week 16
Time frame: 16 weeks
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Other | To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Mean Flow Rate (Qave) | -0.40 millilitre/second | Standard Error 0.475 |
| Drug Group 1 | To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Mean Flow Rate (Qave) | -0.30 millilitre/second | Standard Error 0.509 |
| Drug Group 2 | To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Mean Flow Rate (Qave) | 0.15 millilitre/second | Standard Error 0.505 |
Other Pre-specified
To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Peak Flow Rate (Qmax)
Analysis peak flow rate of Uroflowmetry Parameters and Postvoid Residual Volume Observed Change from Baseline to Week 16
Time frame: 16 weeks
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Other | To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Peak Flow Rate (Qmax) | 4.26 millilitre/second | Standard Error 3.81 |
| Drug Group 1 | To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Peak Flow Rate (Qmax) | 0.61 millilitre/second | Standard Error 4.072 |
| Drug Group 2 | To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Peak Flow Rate (Qmax) | 1.08 millilitre/second | Standard Error 4.043 |
Other Pre-specified
To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Postvoid Residual Volume (PVR)
Analysis postvoid residual volume of Uroflowmetry Parameters and Postvoid Residual Volume Observed Change from Baseline to Week 16
Time frame: 16 weeks
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Other | To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Postvoid Residual Volume (PVR) | -0.08 millilitre | Standard Error 10.365 |
| Drug Group 1 | To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Postvoid Residual Volume (PVR) | 17.63 millilitre | Standard Error 11.325 |
| Drug Group 2 | To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Postvoid Residual Volume (PVR) | -15.19 millilitre | Standard Error 10.925 |
Other Pre-specified
To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter-voided Volume (Vcomp)
Analysis voided of Uroflowmetry Parameters and Postvoid Residual Volume Observed Change from Baseline to Week 16
Time frame: 16 weeks
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Other | To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter-voided Volume (Vcomp) | -49.12 millilitre | Standard Error 21.294 |
| Drug Group 1 | To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter-voided Volume (Vcomp) | -2.28 millilitre | Standard Error 22.501 |
| Drug Group 2 | To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter-voided Volume (Vcomp) | -29.12 millilitre | Standard Error 22.714 |